JR
Therapeutic Areas
Enanta Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zelicapavir (EDP-938) | Respiratory Syncytial Virus (RSV) Infection | Phase 2 |
| EDP-323 | Respiratory Syncytial Virus (RSV) Infection | Phase 2a |
| EDP-235 | COVID-19 (SARS-CoV-2 Infection) | Phase 2 |
| EDP-978 | Type 2 Immune Diseases (e.g., Chronic Spontaneous Urticaria) | Pre-clinical |
| STAT6 Inhibitor Program | Type 2 Inflammatory Diseases | Pre-clinical |
| MRGPRX2 Inhibitor Program | Type 2 Inflammatory Diseases | Pre-clinical |
Leadership Team at Enanta Pharmaceuticals
TL
Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
MP
Matthew P. Kowalsky, J.D.
Chief Legal Officer